Galectin Therapeutics Inc.
DE ˙ DB ˙ US3632252025
1,88 € ↓ -0,05 (-2,59%)
2026-06-03
AKTIENPREIS
SecurityDE:PHPN / Galectin Therapeutics Inc.
InstitutionGeode Capital Management, Llc
Latest Disclosed Ownership612,786 shares
Latest Disclosed Value $ 1,710,550
Geode Capital Management, Llc reports 2.46% increase in ownership of PHPN / Galectin Therapeutics Inc.

On May 15, 2026 - Geode Capital Management, Llc filed a 13F-HR form disclosing ownership of 612,786 shares of Galectin Therapeutics Inc. (DE:PHPN) valued at $1,372,641 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 9, 2026 disclosing 598,074 shares of Galectin Therapeutics Inc.. This represents a change in shares of 2.46% during the quarter. The current value of the position is $1,152,038 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 612,786 14,712 2.46 1,711 -31.30 0.0001
2026-02-09 2025-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 598,074 -34,993 -5.53 2,489 -7.20 0.0002
2025-11-12 2025-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 633,067 -33,124 -4.97 2,682 90.75 0.0002
2025-08-08 2025-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 666,191 -186,515 -21.87 1,406 35.19 0.0001
2025-05-13 2025-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 852,706 -17,883 -2.05 1,041 -7.39 0.0001
2025-02-12 2024-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 870,589 8,047 0.93 1,124 -52.66 0.0001
2024-11-12 2024-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 862,542 20,817 2.47 2,372 24.71 0.0002
2024-08-09 2024-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 841,725 274,564 48.41 1,903 40.37 0.0002
2024-05-13 2024-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 567,161 52,745 10.25 1,356 58.67 0.0001
2024-02-13 2023-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 514,416 3,985 0.78 854 -12.86 0.0001
2023-11-13 2023-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 510,431 -11,855 -2.27 980 30.32 0.0001
2023-08-11 2023-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 522,286 608 0.12 752 -31.32 0.0001
2023-05-15 2023-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 521,678 7,863 1.53 1,096 0.0001
2023-02-13 2022-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 513,815 -87 -0.02 1 -100.00 0.0001
2022-11-14 2022-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 513,902 2,763 0.54 837 25.11 0.0001
2022-08-12 2022-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 511,139 -47,101 -8.44 669 -25.50 0.0001
2022-05-13 2022-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 558,240 -1,488 -0.27 898 -22.45 0.0001
2022-02-11 2021-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 559,728 18,862 3.49 1,158 -44.80 0.0001
2021-11-12 2021-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 540,866 131,853 32.24 2,098 60.40 0.0003
2021-08-13 2021-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 409,013 -236,854 -36.67 1,308 -6.64 0.0002
2021-05-12 2021-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 645,867 3,763 0.59 1,401 -2.57 0.0002
2021-02-12 2020-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 642,104 47,483 7.99 1,438 -9.39 0.0002
2020-11-13 2020-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 594,621 921 0.16 1,587 -12.61 0.0003
2020-08-13 2020-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 593,700 32,332 5.76 1,816 65.09 0.0004
2020-05-14 2020-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 561,368 16,795 3.08 1,100 -29.35 0.0003
2020-02-20 2019-12-31 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 544,573 74,017 15.73 1,557 -9.79 0.0003
2020-02-13 2019-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 544,573 74,017 1,557 198.4260
2019-11-12 2019-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 470,556 1,493 0.32 1,726 -11.31 0.0004
2019-08-14 2019-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 469,063 189,315 67.67 1,946 36.18 0.0005
2019-05-14 2019-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 279,748 52,573 23.14 1,429 83.44 0.0004
2019-03-06 2018-12-31 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 227,175 15,410 7.28 779 -38.76 0.0002
2019-02-13 2018-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 227,175 15,410 779
2018-11-13 2018-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 211,765 9,202 4.54 1,272 -1.24 0.0004
2018-08-14 2018-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 202,563 7,152 3.66 1,288 39.09 0.0004
2018-05-15 2018-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 195,411 0 0.00 926 42.02 0.0003
2018-02-13 2017-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 195,411 0 0.00 652 57.49 0.0002
2017-11-14 2017-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 195,411 0 0.00 414 -13.75 0.0002
2017-08-14 2017-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 195,411 86,400 79.26 480 92.00 0.0002
2017-06-21 2017-03-31 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 109,011 774 0.72 250 135.85 0.0001
2017-05-12 2017-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 109,011 250
2017-02-14 2016-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 108,237 516 0.48 106 -12.40 0.0000
2016-11-10 2016-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 107,721 129 0.12 121 -23.42 0.0001
2016-08-12 2016-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 107,592 0 0.00 158 3.27 0.0001
2016-05-13 2016-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 107,592 -129 -0.12 153 -13.07 0.0001
2016-02-12 2015-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 107,721 7,612 7.60 176 -24.79 0.0001
2015-11-13 2015-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 100,109 258 0.26 234 -13.97 0.0001
2015-08-14 2015-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 99,851 -14,748 -12.87 272 -28.98 0.0002
2015-05-14 2015-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 114,599 4,392 3.99 383 0.26 0.0002
2015-02-12 2014-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 110,207 162 0.15 382 -30.92 0.0002
2014-11-14 2014-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 110,045 108 0.10 553 -63.57 0.0004
2014-08-13 2014-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 109,937 35,865 48.42 1,518 33.86 0.0010
2014-05-14 2014-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 74,072 1,203 1.65 1,134 92.86 0.0008
2014-02-14 2013-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 72,869 28,484 64.17 588 32.73 0.0004
2013-11-14 2013-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 44,385 11,257 33.98 443 214.18 0.0004
2013-08-14 2013-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 33,128 33,128 141 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.